Evolent names Shawn Guertin as new independent nominee for election to its Board of Directors
Evolent Health (NYSE: EVH) has nominated Shawn Guertin, former CFO of CVS Health, Aetna, and Coventry Health Care, to its Board of Directors. The election will take place at the annual stockholders meeting on June 5, 2025. Guertin, who brings nearly 40 years of actuarial, financial, and management experience, served as Executive Vice President and CFO at CVS Health from May 2021 to October 2023.
If elected, Guertin will become the sixth new independent director added to the Board in the past four years, replacing Diane Holder who is not seeking re-election after 14 years of service. This nomination continues Evolent's board refreshment efforts to align with best-in-class corporate governance practices.
Evolent Health (NYSE: EVH) ha nominato Shawn Guertin, ex CFO di CVS Health, Aetna e Coventry Health Care, nel suo Consiglio di Amministrazione. L'elezione avverrà durante l'assemblea annuale degli azionisti il 5 giugno 2025. Guertin, che vanta quasi 40 anni di esperienza in ambito attuariale, finanziario e gestionale, è stato Vicepresidente Esecutivo e CFO di CVS Health da maggio 2021 a ottobre 2023.
Se eletto, Guertin diventerà il sesto nuovo direttore indipendente inserito nel Consiglio negli ultimi quattro anni, sostituendo Diane Holder, che dopo 14 anni di servizio non si ricandiderà. Questa nomina prosegue gli sforzi di rinnovo del Consiglio di Evolent per allinearsi alle migliori pratiche di governance aziendale.
Evolent Health (NYSE: EVH) ha nominado a Shawn Guertin, ex CFO de CVS Health, Aetna y Coventry Health Care, para su Junta Directiva. La elección se llevará a cabo en la reunión anual de accionistas el 5 de junio de 2025. Guertin, con casi 40 años de experiencia en áreas actuariales, financieras y de gestión, fue Vicepresidente Ejecutivo y CFO de CVS Health desde mayo de 2021 hasta octubre de 2023.
Si es elegido, Guertin será el sexto nuevo director independiente incorporado a la Junta en los últimos cuatro años, reemplazando a Diane Holder, quien tras 14 años de servicio no buscará la reelección. Esta nominación continúa los esfuerzos de renovación de la Junta de Evolent para alinearse con las mejores prácticas de gobernanza corporativa.
Evolent Health (NYSE: EVH)는 CVS Health, Aetna, Coventry Health Care의 전 CFO인 Shawn Guertin을 이사회 이사 후보로 지명했습니다. 선출은 2025년 6월 5일 연례 주주총회에서 진행됩니다. Guertin은 약 40년간의 보험계리, 재무 및 경영 경험을 보유하고 있으며, 2021년 5월부터 2023년 10월까지 CVS Health의 부사장 겸 CFO로 재직했습니다.
선출될 경우, Guertin은 지난 4년간 이사회에 새로 합류한 6번째 독립 이사가 되며, 14년간 재임한 Diane Holder를 대신하게 됩니다. 이번 지명은 Evolent가 최고 수준의 기업 지배구조 관행에 부합하도록 이사회를 새롭게 구성하려는 노력을 이어가는 것입니다.
Evolent Health (NYSE : EVH) a nommé Shawn Guertin, ancien directeur financier de CVS Health, Aetna et Coventry Health Care, à son conseil d'administration. L'élection aura lieu lors de l'assemblée annuelle des actionnaires le 5 juin 2025. Guertin, qui possède près de 40 ans d'expérience en actuariat, finance et gestion, a été vice-président exécutif et directeur financier de CVS Health de mai 2021 à octobre 2023.
Si élu, Guertin deviendra le sixième nouveau directeur indépendant ajouté au conseil au cours des quatre dernières années, succédant à Diane Holder, qui ne se représentera pas après 14 ans de service. Cette nomination s'inscrit dans la continuité des efforts d'Evolent pour renouveler son conseil et s'aligner sur les meilleures pratiques de gouvernance d'entreprise.
Evolent Health (NYSE: EVH) hat Shawn Guertin, den ehemaligen CFO von CVS Health, Aetna und Coventry Health Care, für seinen Vorstand nominiert. Die Wahl findet auf der jährlichen Hauptversammlung der Aktionäre am 5. Juni 2025 statt. Guertin bringt fast 40 Jahre Erfahrung in den Bereichen Aktuariat, Finanzen und Management mit und war von Mai 2021 bis Oktober 2023 Executive Vice President und CFO bei CVS Health.
Wird er gewählt, ist Guertin der sechste neue unabhängige Direktor, der in den vergangenen vier Jahren in den Vorstand berufen wird und ersetzt Diane Holder, die nach 14 Jahren nicht erneut kandidiert. Diese Nominierung setzt Evolents Bemühungen zur Erneuerung des Vorstands fort, um sich an den besten Praktiken der Unternehmensführung auszurichten.
- Addition of seasoned healthcare executive with extensive financial and operational experience
- Demonstrates commitment to board refreshment and corporate governance best practices
- Brings valuable expertise from major healthcare companies (CVS Health, Aetna, Coventry)
- Loss of long-term board member Diane Holder's institutional knowledge
- Former CFO of CVS Health, Aetna and Coventry Health Care brings deep experience driving growth and profitability.
- Mr. Guertin's nomination represents continuation of Evolent's board refreshment efforts.
The Board has recommended Mr. Shawn Guertin for election. Mr. Guertin is an insurance and health care executive with nearly 40 years of actuarial, financial and management experience. Most recently, he served as Executive Vice President and Chief Financial Officer for CVS Health Corporation from May 2021 to October 2023.
Mr. Guertin's nomination follows a search process by the Board's Nominating and Governance Committee to refresh an independent director position.
"It is an honor to be nominated to the Board," said Mr. Guertin. "I believe that Evolent offers a differentiated product for payers seeking to deliver top-quality clinical outcomes and health care value to members living with complex health conditions. I'm excited for the opportunity to help drive shareholder value."
If elected, Mr. Guertin will be the sixth new independent director added to the Board in the past four years, reflecting the Board's emphasis on ensuring its corporate governance aligns with best-in-class practices.
"Shawn brings an impressive track record of driving growth and profitability in the health care industry, and we are excited about the opportunity to have him join the Board," said Evolent Board Chair Cheryl Scott.
Evolent Co-Founder and Chief Executive Officer Seth Blackley stated, "Shawn is a highly respected leader from some of America's best-known health care brands. We look forward to benefiting from his guidance and his passion for our mission."
Mr. Guertin would take the seat currently held by Diane Holder, who is not seeking re-election.
"I am incredibly grateful to Diane for her contributions to Evolent and the Board over the last 14 years. Diane has helped establish the company as a leader in value-based specialty care, and her legacy will always be linked to Evolent," said Mr. Blackley.
About Shawn Guertin
Shawn Guertin served as the Executive Vice President and Chief Financial Officer at CVS Health Corporation from May 2021 to October 2023 and remained with CVS Health through May 2024. From January 2014 to May 2019, Mr. Guertin served as the Executive Vice President, CFO and Chief Enterprise Risk Officer at Aetna, Inc. and as the Senior Vice President, CFO and Chief Enterprise Risk Officer from February 2013 to January 2014. Prior to that role, Mr. Guertin served as the Head of Business Segment Finance at Aetna from April 2011 to February 2013. Previously, Mr. Guertin held several leadership roles at Coventry Health Care, Inc. from January 1998 to December 2009, including CFO and Treasurer from January 2005 to December 2009. Mr. Guertin previously served on the boards of directors of DaVita, Inc. and TriNet Group, Inc. He received a B.A. in Mathematics from
About Evolent Health
Evolent (NYSE: EVH) specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable. Evolent serves a national base of leading payers and providers and is consistently recognized as a top place to work in health care nationally. Learn more about how Evolent is changing the way health care is delivered by visiting https://ir.evolent.com.
Important Additional Information and Where to Find it
Evolent Health, Inc. (the "Company") intends to file a proxy statement with the Securities and Exchange Commission (the "SEC") in connection with the solicitation of proxies for the Company's 2025 Annual Meeting of Stockholders (the "Proxy Statement" and such meeting the "Annual Meeting"). The Company, its directors and certain of its executive officers will be participants in the solicitation of proxies from shareholders in respect of the Annual Meeting. Information regarding the names of the Company's directors and executive officers and their respective interests in the Company by security holdings or otherwise are set forth in the Company's proxy statement for the 2024 Annual Meeting of Stockholders, filed with the SEC on April 26, 2024 (the "2024 Proxy Statement") and the Company's Current Report on Form 8-K, filed with the SEC on February 4, 2025. To the extent holdings of such participants in the Company's securities have changed since the amounts described in the 2024 Proxy Statement, such changes have been reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Changes in Beneficial Ownership on Form 4 filed with the SEC. Details concerning the nominees of the Company's Board of Directors for election at the Annual Meeting will be included in the Proxy Statement. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SHAREHOLDERS OF THE COMPANY ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH OR FURNISHED TO THE SEC, INCLUDING THE COMPANY'S DEFINITIVE PROXY STATEMENT AND ANY SUPPLEMENTS THERETO BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and shareholders will be able to obtain a copy of the definitive Proxy Statement and other documents filed by the Company free of charge from the SEC's website, www.sec.gov. The Company's shareholders will also be able to obtain, without charge, a copy of the definitive Proxy Statement and other relevant filed documents by directing a request by mail to Evolent Health, Inc., Attention: Investor Relations, 1812 N. Moore Street, Suite 1705,
Evolent Contact
investorrelations@evolent.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/evolent-names-shawn-guertin-as-new-independent-nominee-for-election-to-its-board-of-directors-302433841.html
SOURCE Evolent Health, Inc.
FAQ
When will Shawn Guertin join Evolent Health's (EVH) Board of Directors?
What experience does Shawn Guertin bring to Evolent Health's board?
How many new independent directors has EVH added in recent years?
Who is Shawn Guertin replacing on Evolent Health's board?
